71 results on '"T, Borsos"'
Search Results
2. Metabolic requirements for hormone-induced resistance to antibody-complement mediated killing of tumor cells.
3. Hemolytic efficiency of cell-bound IgM: evidence that IgM-C1 complexes activate C4 molecules not hemolytic with homologous C2--C9.
4. Studies on the terminal stages of immune hemolysis. IV. Effect of metal salts.
5. Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. I. Evidence for the existence of an intermediate, T.
6. Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9.
7. Binding and activation of hemolytic complement by IgG antibodies: cooperativity between antibodies of different hapten specificity.
8. Complement inhibitor(s) released by leukocytes. I. Pretreatment of sheep erythrocytes with supernatants of mouse spleen and thymus cells inhibit whole complement activity and C2 utilization.
9. Mathematical analysis of the reaction of EAC1-8 with C9: identification of parameters defining conditions for molecular titration.
10. Studies on the interaction between protein A and immunoglobulin G. I. Effect of protein A on the functional activity of IgG.
11. Studies on the terminal stages of immune hemolysis. V. Evidence that not all complement-produced transmembrane channels are equal.
12. Effect of concanavalin A on the killing of tumor cells by antibody and complement.
13. Lysis of hapten-labeled cells by anti-hapten IgG and complement: effect of cell surface hapten density.
14. Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid.
15. Activation of human C1r: Western blot analysis reveals slow and dose-dependent activation.
16. Studies on the terminal stages of immune hemolysis. VI. Osmotic blockers of differing Stokes' radii detect complement-induced transmembrane channels of differing size.
17. Lysis of tumor cells by antibody and complement. II. Lack of correlation between amount of C4 and C3 fixed and cell lysis.
18. Identification of lipids synthesized and released by tumor cells under attack by antibody and complement.
19. Cell-bound C4b resists reduction by reducing agents: analysis by chain structure and by hemolytic activity.
20. Quantitative comparison of techniques used to measure complement-mediated cytotoxicity of nucleated cells.
21. Distinction between C8-mediated and C8/C9-mediated hemolysis on the basis of independent 86Rb and hemoglobin release.
22. Immunochemical quantitaion of the third component of guinea pig complement in fluid phase and bound to cell surfaces.
23. Studies on the terminal stages of antibody-complement mediated killing of a tumor cell. III. Effect of membrane active agents.
24. Anti-hapten IgG antibodies bound to cell surface hapten: anti-IgG antibody prevents dissociation as measured with fluid phase hapten.
25. Lysis of tumor cells by antibody and complement. VII. Complement-dependent 86Rb release--a nonlethal event?
26. Immunochemical quantitation of cell bound C4.
27. Activation of human C1: analysis with Western blotting reveals slow self-activation.
28. Analysis of the colloid osmotic step of complement-mediated immune hemolysis.
29. Antigenic relationship between the fourth component of human and guinea pig complement.
30. Identification of lipids associated with the ability of tumor cells to resist humoral immune attack.
31. Stimulation of the synthesis and release of lipids in tumor cells under attack by antibody and C.
32. Effect of concanavalin A on the classical complement pathway.
33. Studies on the terminal stages of immune hemolysis. III. Distinction between the insertion of C9 and the formation of a transmembrane channel.
34. Lysis of tumor cells by antibody and complement. III. Lack of correlation between antigen movement and cell lysis.
35. Studies on the terminal stages of antibody-complement-mediated killing of a tumor cell. II. Inhibition of transformation of T to dead cells by 3'5' cAMP.
36. Synthesis of specific lipids associated with the hormone-induced resistance of tumor cells to humoral immune killing.
37. C4 does not bind to human and rabbit IgM during activation of the classical complement pathway on the red cell.
38. Studies on the interaction between protein A and immunoglobulin G. II. Composition and activity of complexes formed between protein A and IgG.
39. Lysis of tumor cells by antibody and complement. VI. Enhanced killing of enzyme-pretreated tumor cells.
40. Naturally soluble tumor antigens from guinea pig hepatomas: isolation and partial characterization.
41. THE INTERACTION BETWEEN CARRAGEENAN AND THE FIRST COMPONENT OF COMPLEMENT.
42. Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. I. Functional differences among C4 sites on cell surfaces.
43. STUDIES ON THE TERMINAL STEPS OF IMMUNE HEMOLYSIS. I. INHIBITION BY TRISODIUM ETHYLENEDIAMINETETRAACETATE (EDTA).
44. Activation of the first component of complement evidence for an internal activation step.
45. ESTIMATION OF MOLECULAR SIZE OF COMPLEMENT COMPONENTS BY SEPHADEX CHROMATOGRAPHY.
46. CHROMATOGRAPHIC SEPARATION OF THE FIRST COMPONENT OF COMPLEMENT AND ITS ASSAY ON A MOLECULAR BASIS.
47. C'-1 fixation by human isoagglutinins: fixation of C'-1 by gamma-G and gamma-M but not by gamma-A antibody.
48. Immune hemolysis and the functional properties of the second (C2) and fourth (C4) components of complement. 3. The hemolytic efficiency of human and guinea pig C2 and C4.
49. ACTION OF THE FIRST COMPONENT OF COMPLEMENT. ACTIVITATION OF C'1 TO C'1A IN THE HEMOLYTIC SYSTEM.
50. Hemolysin titration based on fixation of the activated first component of complement: evidence that one molecule of hemolysin suffices to sensitize an erythrocyte.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.